Nephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy.
We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with griseofulvin. To our knowledge, this is the first case of griseofulvin-exacerbated lupus in which nephrotic syndrome has been observed.
Bonilla-Felix
M
M
Department of Pediatrics, University of Texas, Health Science Center at Houston, USA.
Verani
R
R
Vanasse
L G
LG
Hebert
A
A
D000293:Adolescent; D000974:Antibodies, Antinuclear / Q000032:analysis; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019084:Fluorescent Antibody Technique, Indirect; D006118:Griseofulvin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D008297:Male; D008854:Microscopy, Electron; D009404:Nephrotic Syndrome / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D014006:Tinea Capitis / Q000188:drug therapy
D000974:Antibodies, Antinuclear; D000935:Antifungal Agents; D006118:Griseofulvin